CIK 0001743881 · Large accelerated filer
BridgeBio Pharma, Inc.
Sign in to watch- Ticker
- BBIO
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- (650) 391-9740
- Business address
- 3160 PORTER DR., SUITE 250, PALO ALTO, CA, 94304
- Former names
- BridgeBio Pharma LLC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $4,563,798
- in 3 filings, $4.6M under 10b5-1 plans
Net −$4,563,798. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-11-16 | Kumar Neil Chief Executive Officer | Option exercise · Restricted Stock Units | −19,599 | 176,394 | ||
| 2025-11-16 | Kumar Neil Chief Executive Officer | Option exercise · Restricted Stock Units | −11,554 | 150,199 | ||
| 2025-11-16 | Trimarchi Thomas President and CFO | Shares withheld for taxes 10b5-1 | −21,317 | $66.39 | $1.4M | 399,764 |
| 2025-11-16 | Apuli Maricel Chief Accounting Officer | Shares withheld for taxes | −4,781 | $66.39 | $317K | 132,297 |
| 2025-11-12 | Valantine Hannah Director | Option exercise | +25,484 | $48.45 | $1.2M | 32,949 |
| 2025-11-12 | Valantine Hannah Director | Sale | −25,484 | $66.07 | $1.7M | 7,465 |
| 2025-11-12 | Valantine Hannah Director | Option exercise · Stock Option (Right to Buy) | −25,484 | 25,484 | ||
| 2025-11-07 | Kumar Neil Chief Executive Officer | Sale 10b5-1 | −12,492 | $61.14 | $764K | 4,605,955 |
| 2025-11-07 | Kumar Neil Chief Executive Officer | Sale 10b5-1 | −7,308 | $61.87 | $452K | 4,598,647 |
| 2025-11-07 | Kumar Neil Chief Executive Officer | Sale 10b5-1 | −200 | $62.81 | $13K | 4,598,447 |
| 2025-11-07 | Kumar Neil Chief Executive Officer | Sale 10b5-1 | −12,234 | $61.13 | $748K | 803,452 |
| 2025-11-07 | Kumar Neil Chief Executive Officer | Sale 10b5-1 | −7,546 | $61.87 | $467K | 795,906 |
| 2025-11-07 | Kumar Neil Chief Executive Officer | Sale 10b5-1 | −220 | $62.79 | $14K | 795,686 |
| 2025-11-06 | Kumar Neil Chief Executive Officer | Sale 10b5-1 | −12,576 | $62.91 | $791K | 4,625,871 |
| 2025-11-06 | Kumar Neil Chief Executive Officer | Sale 10b5-1 | −7,324 | $63.55 | $465K | 4,618,547 |
| 2025-11-06 | Kumar Neil Chief Executive Officer | Sale 10b5-1 | −100 | $64.39 | $6K | 4,618,447 |
| 2025-11-06 | Kumar Neil Chief Executive Officer | Sale 10b5-1 | −12,529 | $62.91 | $788K | 823,157 |
| 2025-11-06 | Kumar Neil Chief Executive Officer | Sale 10b5-1 | −7,371 | $63.56 | $468K | 815,786 |
| 2025-11-06 | Kumar Neil Chief Executive Officer | Sale 10b5-1 | −100 | $64.39 | $6K | 815,686 |
| 2025-11-06 | DANIELS RONALD J Director | Option exercise | +61,031 | $34.65 | $2.1M | 78,022 |
Page 13 of 19 · 379 trades